Vericel Corp — Earnings Release 2011

Aug 15, 2011

8-K 1 document.htm FORM 8-K FILING DOCUMENT html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd" Form 8-K Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 15, 2011

Aastrom Biosciences, Inc. (Exact name of registrant as specified in its charter)

Registrant's State of Inc, File and IRS Number

Michigan	0-22025	943096597
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Registrant's Postal Addess and Zip Code

24 Frank Lloyd Wright Drive P.O. Box 376 Ann Arbor, Michigan	48106
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (734) 930-5555

______________ (Former name or former address, if changed since last report)

Simultaneous filing obligation checkboxes

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On August 15, 2011 the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

Exhibit 99.1. Press release dated August 15, 2011

Registrant's Signature

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aastrom Biosciences, Inc. (Registrant)
August 15, 2011 (Date)	/s/ TIMOTHY M. MAYLEBEN Timothy M. Mayleben Chief Executive Officer and President

Exhibit Listing

Exhibit Index
99.1	Press release dated August 15, 2011